The test is being developed to support analysis across a range of tumour types, including breast, lung, colon and bladder cancers, as well as central nervous system tumours and lymphoma.
A $6 million research collaboration to develop a next-generation clinical-grade cancer profiling test has been launched by Singapore-based precision oncology company Lucence, together with the Diagnostics Development Hub (DxD Hub), hosted by the Agency for Science, Technology and Research, and the National Cancer Centre Singapore (NCCS).
Called UNITED 2.0, the three-year initiative aims to advance precision diagnostics by building a more comprehensive genomic test that can help doctors match patients with targeted cancer treatments.
